PROM1 and glioma: Another study showed that a combinatory treatment of RO4929097 with standard-of-care TMZ plus radiation therapy decreased 3D spheroid growth, cell proliferation, and expression of stemness markers (CD133, SOX2, and NESTIN), leading to a marked reduction in clonogenic survival of primary and established glioma cell lines [117].